Skip to main content
 

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

Accept

 
News

BeiGene News

See all News
  • January 13, 2020
    EUSA Pharma and BeiGene Announce Exclusive Development and Commercialization Agreement for SYLVANT® and QARZIBA®▼ in Greater China

    EUSA Pharma and BeiGene Announce Exclusive Development and Commercialization Agreement for SYLVANT® and QARZIBA®▼ in Greater China

  • January 8, 2020
    BeiGene to Present at the 38th Annual J.P. Morgan Healthcare Conference

    BeiGene to Present at the 38th Annual J.P. Morgan Healthcare Conference

  • January 3, 2020
    Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing

    Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing

  • January 2, 2020
    BeiGene Announces Closing of Amgen Global Strategic Oncology Collaboration and Equity Investment

    BeiGene Announces Closing of Amgen Global Strategic Oncology Collaboration and Equity Investment

  • December 27, 2019
    China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Classical Hodgkin’s Lymphoma Who Have Received at Least Two Prior Therapies

    China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Classical Hodgkin’s Lymphoma Who Have Received at Least Two Prior Therapies

  • December 22, 2019
    BeiGene Announces Acceptance of a Supplemental New Drug Application in China for REVLIMID® in Relapsed or Refractory Indolent Lymphoma

    BeiGene Announces Acceptance of a Supplemental New Drug Application in China for REVLIMID® in Relapsed or Refractory Indolent Lymphoma

  • BeiGene Facts
  • Founded 2010
  • Listings NASDAQ: BGNE   HKEX: 06160
  • Internally Developed
    Clinical Candidates 6
  • Marketed Products
    in China 3
  • Global Team 3000+
story
 
  • 2010

    • BeiGene was founded as a research and development company
    BeiGene Co-Founders, John V. Oyler and Xiaodong Wang, Ph.D.
  • 2012

    • Began work on an anti-PD-1 antibody and a BTK inhibitor
    Immuno-oncology Therapies
  • 2014

    • Started clinical trials of pamiparib and zanubrutinib
    Clinical Researcher
  • 2016

    • Went public on the Nasdaq, with $182 million initial public offering
    First China biotech to go public on the Nasdaq
  • 2018

    • 50+ ongoing or planned clinical trials
    BeiGene expands global operations
  • 2019

    • Received first FDA approval for BRUKINSA™ (zanubrutinib)
    • Received first approval for tislelizumab in China
    2019

Our Story

Breaking Boundaries From the Beginning

From our start in Beijing with a handful of scientists and developers, to today, with a global team, a rich pipeline, strong partnerships, and commercial products. We have accomplished so much in a short time, and yet there is so much still to do.

Our Story

Partnering

Partnerships that Extend Around the Globe

BeiGene is the partner of choice in China for development and commercialization. Read more about our current partnerships and opportunities to build business relationships.

Partners

ZymeworksBioAtla LogoLeapSeattleAmbrx LogoMirati LogoMei PharmaAmgen logo

Our Patients

Our Commitment to Patients

At BeiGene we are focused not only on the underserved global cancer patient population, but also on individual people fighting their illnesses.

Patients

Careers
 

Careers

Join Our
Team

We’re looking for highly motivated colleagues who can collaborate with us as we build a company that will have a lasting impact on the global fight against cancer.

Careers